Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co R&D per Employee

The R&D Spending per Employee of Shanghai Fudan Forward S&T Co (600624.SS) as of Nov 2, 2026 is 22,163.25 CNY. In the previous year, R&D Spending per Employee was 21,937.19 CNY — a change of 1.03% (higher).

R&D per Employee

22,163.25CNY

YoY

1.03%

Last updated:

R&D Spending per Employee of Shanghai Fudan Forward S&T Co is 2025 22,163.25 CNY. R&D Spending per Employee of Shanghai Fudan Forward S&T Co was 2024 21,937.19 CNY. It decreases by 1.03% higher compared to the previous year.

The Shanghai Fudan Forward S&T Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
29,022.08 CNY
Jan 1, 2019
37,369.97 CNY
Jan 1, 2020
35,741.11 CNY
Jan 1, 2021
34,377.29 CNY
Jan 1, 2022
28,070.90 CNY
Jan 1, 2023
24,625.65 CNY
Jan 1, 2024
21,937.19 CNY
Jan 1, 2025
22,163.25 CNY
The Shanghai Fudan Forward S&T Co R&D per Employee history
YEARR&D per EmployeeYoY
22,163.25CNY+1.03%
21,937.19CNY-10.92%
24,625.65CNY-12.27%
28,070.90CNY-18.34%
34,377.29CNY-3.82%
35,741.11CNY-4.36%
37,369.97CNY+28.76%
29,022.08CNY+25.04%
23,210.47CNY+12.42%
20,646.07CNY+0.94%
20,452.93CNY-21.00%
25,889.31CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

R&D Spending per Employee of Shanghai Fudan Forward S&T Co is 22,163.25 CNY in 2025.

R&D Spending per Employee of Shanghai Fudan Forward S&T Co changed from 21,937.19 CNY to 22,163.25 CNY, representing a 1.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Shanghai Fudan Forward S&T Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Shanghai Fudan Forward S&T Co

All Key Metrics — Shanghai Fudan Forward S&T Co